- Home
- ATYR
as 11-20-2024 4:00pm EST
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 228.1M | IPO Year: | 2015 |
| Target Price: | $19.25 | AVG Volume (30 days): | 857.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.14 - $3.80 | Next Earning Date: | 11-07-2024 |
| Revenue: | $235,000 | Revenue Growth: | -97.81% |
| Revenue Growth (this year): | -28.67% | Revenue Growth (next year): | 2057.69% |
Latest aTyr Pharma Inc. Common Stock News
ATYR Breaking Stock News: Dive into ATYR Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
GlobeNewswire
14 days ago
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
GlobeNewswire
21 days ago
aTyr Pharma to Present at Upcoming Investor Conferences
Simply Wall St.
a month ago
High Growth Tech Stocks to Watch in October 2024
Newsfile
a month ago
aTyr Pharma to Present at the LD Micro Main Event XVII in October
GlobeNewswire
a month ago
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
GlobeNewswire
2 months ago
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
GlobeNewswire
3 months ago
aTyr Pharma to Participate in September Investor Conferences
Compare ATYR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATYR aTyr Pharma Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.